rusfertide reduces need for therapeutic phlebotomy in pv patients
Published 3 years ago • 358 plays • Length 5:56Download video MP4
Download video MP3
Similar videos
-
3:23
the role of rusfertide in polycythemia vera
-
1:56
rationale for verify: rusfertide added to ongoing therapy in patients with polycythemia vera
-
9:07
revive: targeted therapy for uncontrolled erythrocytosis in pv with rusfertide
-
7:26
rusfertide: a promising option to control hematocrit levels in patients with polycythemia vera
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
1:25
the need for disease-modifying agents in pv to prevent disease progression
-
2:08
phase iii trial of rusfertide in patients with polycythemia vera
-
5:42
an update on revive: rusfertide in patients with polycythemia vera
-
1:55
an update on the safety and efficacy of rusfertide in polycythemia vera
-
2:55
pv-aim: using machine learning to predict resistance to hydroxyurea therapy in patients with pv
-
4:51
marina kremyanskaya: ptg-300 reduces therapeutic phlebotomy in patients with polycythemia vera
-
1:30
the verify trial: rusfertide in patients with polycythemia vera
-
1:52
cytoreductive therapy for patients with pv
-
1:39
upcoming agents in et and pv
-
3:59
pv: outcomes, unmet needs, and therapeutic strategies
-
2:14
risk-adapted treatment of et & pv
-
3:29
current approaches and new approvals in mf and pv
-
1:49
current and future therapies for pv: ropeginterferon alfa-2b
-
0:35
novel therapeutics in essential thrombocythemia